Neuraxpharm, a specialty pharmaceutical company focused on the central nervous system (CNS), has appointed Tom Coogan as country manager for Ireland.
The appointment reinforces Neuraxpharm’s management team in Ireland with an experienced executive who will focus on establishing Neuraxpharm as CNS
specialist in the north-western European country.
With Tom Coogan, Neuraxpharm can rely on a dedicated entrepreneur with highly relevant market expertise. He has a proven track record in successfully building the Ireland business of Grünenthal Pharma Ltd (Grünenthal) to become a leading player in Ireland in the field of pain management and related diseases.
At Neuraxpharm, he will focus on advancing the company’s position in Ireland by applying his profound expertise of the Irish market to strategically grow the business further and ensure the successful development of the product portfolio in line with the group’s.
Tom Coogan chas nearly thirty years of experience in the pharmaceutical industry. He joins Neuraxpharm from Grünenthal, where he most recently served as Managing Director. Since 2004, he has successfully built Grünenthal’s Ireland business to become a top 20 ranked Pharma Company in Ireland.
He was national sales manager at Lundbeck Ireland from 2001 to 2004, having previously held positions as a CNS Hospital Specialist at Organon from 1999 to 2001 and as a Hospital Representative at Upjohn from 1993 to 1998.
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “We are very pleased to announce the appointment of Tom Coogan as our new country manager for Ireland. We are certain that with his experience and hands-on mentality, Tom will help us elevate our business in Ireland to the next level. I am looking forward to working with him and to jointly expanding our position as the leading CNS company with a broad and diverse portfolio.”
Tom Coogan said: “With its acquisition of Medinutrix in 2020, Neuraxpharm has become a serious player in Ireland. I look forward to working with my new team and to making available all of my expertise to further expand our business.”
Neuraxpharm has established its operations in Ireland in December 2020 through the acquisition of the specialty pharmaceutical company Medinutrix (trading as Aribamed) and will leverage its CNS expertise to provide access to suitable products out of its extensive portfolio, including the recently acquired Bucolic for
emergency treatment of epileptic children and adolescents.
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
Listen: Longevity, Eastern wisdom and Western science
Fundamental principles of healthcare digital twins
Tackling the diagnostic testing sustainability problem
Gym-going men ‘unaware’ of protein risk to fertility
Anti-choke mug protects Parkinson’s patients
- News3 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- AI5 days ago
AI model predicts breast cancer risk without racial bias
- Medtech4 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI2 weeks ago
Humans make better cancer treatment decisions than AI, study finds